|
Report Date : |
21.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
TEIJIN PHARMA LTD |
|
|
|
|
Registered Office : |
Kasumigaseki Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2012 |
|
|
|
|
Date of Incorporation : |
April
2002 |
|
|
|
|
Com. Reg. No.: |
0100-01-078242
(Tokyo-Chiyodaku) |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals, pharmaceutical devices |
|
|
|
|
No. of Employees : |
1,864 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
TEIJIN PHARMA LTD
Teijin Pharma KK
Kasumigaseki
Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013 JAPAN
Tel:
03-3506-4077 Fax: 03-3506-4498
URL: http://www.teijin-pharma.co.jp
E-Mail
address: (thru the URL)
Mfg of
pharmaceuticals, pharmaceutical devices
83
locations nationwide
USA,
UK, Korea, China (2), Spain
Iwakuni
(2)
KENTARO
ARAO, PRES Hiroshi Uno, s/mgn
dir
Kiyoshi
Sakauchi, mgn dir Hidekazu
Kuribayashi, dir
Takashi
Kimura, dir Tomohiro
Ohta, dir
Yen
Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen 99,669 M
PAYMENTS REGULAR CAPITAL Yen 10,000 M
TREND UP WORTH Yen 43,181 M
STARTED 2002 EMPLOYES 1,864
MFR OF PHARMACEUTICALS, WHOLLY OWNED BY TEIJIN LTD.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject company was established on the basis of a division separated
from Teijin Ltd (See REGISTRATION). This firm specializes in mfg pharmaceuticals
& medical devices for: bone & joint diseases, respiratory diseases, cardiovascular
& metabolic diseases, other. In
addition, the firm developed home medical care services, home oxygen therapy
continuous positive airway pressure (CPAP) therapy, a treatment for sleep apnea
syndrome, and now holds the largest share in each domestic market.
The sales volume for Mar/2011 fiscal term amounted to Yen 99,669
million, a 3% up from Yen 96,992 million in the previous term. Demand for home medical care services was
brisk and rose. The recurring profit was
posted at Yen 24,808 million and the net profit at Yen 14,731 million,
respectively, compared with Yen 24,085 million recurring profit and Yen 13,500
million net profit, respectively, a year ago.
For the term that ended Mar 2012 the recurring profit was projected at
Yen 25,000 million and the net profit at Yen 15,000 million respectively, on a
3% rise in turnover, to Yen 102,500 million.
Final results are yet to be released.
The financial situation is considered FAIR and good for ORDINARY
business engagements.
Date Registered: Apr 2002
Regd No.: 0100-01-078242 (Tokyo-Chiyodaku)
Legal Status:
Limited Company (Kabushiki Kaisha)
Authorized:
800,000 shares
Issued:
200,000 shares
Sum: Yen 10,000 million
Major shareholders (%): Teijin Ltd* (100)
*.. Major synthetic textile mfr, Tokyo, founded 1918, listed Tokyo S/E, capital Yen 7,816 million, sales Yen 854,370 million, operating profit Yen 34,044 million, recurring profit Yen 34,283 million, net profit Yen 11,979 million, total assets Yen 762,118 million, net worth Yen 312,217 million, employees 17,611, pres Shigeo Ohyagi
Consolidated
Financials are attached (See SUPPLEMENTS)
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures
pharmaceuticals & medical devices for: bone & joint diseases,
respiratory diseases, cardiovascular & metabolic diseases; home care
medical services, home oxygen therapy, other (--100%).
Clients: [Mfrs,
wholesalers] Teijin Home-Care Therapy, Kaketsuken Corp, Sakai Inc, Japan Care
Service Group, other
No. of accounts: 500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Teijin Ltd, Kaketsuken Corp, Fuji Bio Medix, Nichiko Pharma,
Morishita Jintan Co, Asuka Pharmaceutical Co, other
Payment record: Regular
Location: Business area in
Tokyo. Office premises at the caption
address are leased and maintained satisfactorily.
Bank References:
MUFG
(Tokyo)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
31/03/2012 |
31/03/2011 |
31/03/2010 |
31/03/2009 |
|
|
Annual
Sales |
|
102,500 |
99,669 |
96,992 |
96,996 |
|
Recur.
Profit |
|
25,000 |
24,808 |
24,085 |
22,732 |
|
Net
Profit |
|
15,000 |
14,731 |
13,500 |
12,333 |
|
Total
Assets |
|
|
75,609 |
76,556 |
78,347 |
|
Current
Assets |
|
|
43,012 |
45,285 |
45,430 |
|
Current
Liabs |
|
|
26,335 |
26,489 |
25,126 |
|
Net
Worth |
|
|
43,181 |
44,547 |
47,717 |
|
Capital,
Paid-Up |
|
|
10,000 |
10,000 |
10,000 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
2.84 |
2.76 |
0.00 |
2.05 |
|
|
Current Ratio |
|
.. |
163.33 |
170.96 |
180.81 |
|
N.Worth Ratio |
.. |
57.11 |
58.19 |
60.90 |
|
|
R.Profit/Sales |
|
24.39 |
24.89 |
24.83 |
23.44 |
|
N.Profit/Sales |
14.63 |
14.78 |
13.92 |
12.71 |
|
|
Return On Equity |
.. |
34.11 |
30.31 |
25.85 |
|
Notes:
Forecast (or estimated) figures for the 31/03/2012 fiscal term.
CONSOLIDATED FINANCIALS OF THE PARENT,
TEIJIN LTD
|
FINANCES: (Consolidated
in million yen) |
|
|||||
|
|
|
Terms Ending: |
31/03/2012 |
31/03/2011 |
||
|
INCOME STATEMENT |
|
|
||||
|
|
Annual Sales |
|
854,370 |
815,656 |
||
|
|
Cost of Sales |
629,152 |
586,261 |
|||
|
|
GROSS PROFIT |
225,218 |
229,394 |
|||
|
|
Selling & Adm Costs |
191,174 |
180,834 |
|||
|
|
OPERATING PROFIT |
34,044 |
48,560 |
|||
|
|
Non-Operating P/L |
239 |
1,785 |
|||
|
|
RECURRING PROFIT |
34,283 |
50,345 |
|||
|
|
NET PROFIT |
11,979 |
25,182 |
|||
|
BALANCE SHEET |
|
|
|
|||
|
|
Cash |
|
33,440 |
28,612 |
||
|
|
Receivables |
|
172,087 |
156,132 |
||
|
|
Inventory |
|
108,996 |
105,507 |
||
|
|
Securities, Marketable |
|
|
|||
|
|
Other Current Assets |
47,266 |
46,643 |
|||
|
|
TOTAL CURRENT ASSETS |
361,789 |
336,894 |
|||
|
|
Property & Equipment |
244,301 |
259,659 |
|||
|
|
Intangibles |
|
62,690 |
67,615 |
||
|
|
Investments, Other Fixed Assets |
93,338 |
97,366 |
|||
|
|
TOTAL ASSETS |
762,118 |
761,534 |
|||
|
|
Payables |
|
90,225 |
87,283 |
||
|
|
Short-Term Bank Loans |
61,554 |
44,568 |
|||
|
|
|
|
|
|
||
|
|
Other Current Liabs |
126,172 |
112,919 |
|||
|
|
TOTAL CURRENT LIABS |
277,951 |
244,770 |
|||
|
|
Debentures |
|
30,000 |
30,000 |
||
|
|
Long-Term Bank Loans |
102,191 |
138,870 |
|||
|
|
Reserve for Retirement Allw |
18,783 |
18,153 |
|||
|
|
Other Debts |
|
20,976 |
22,043 |
||
|
|
TOTAL LIABILITIES |
449,901 |
453,836 |
|||
|
|
MINORITY INTERESTS |
|
|
|||
|
|
Common
stock |
70,816 |
70,816 |
|||
|
|
Additional
paid-in capital |
101,389 |
101,373 |
|||
|
|
Retained
earnings |
141,441 |
135,385 |
|||
|
|
Evaluation
p/l on investments/securities |
9,913 |
10,823 |
|||
|
|
Others |
|
(11,215) |
(10,548) |
||
|
|
Treasury
stock, at cost |
(127) |
(151) |
|||
|
|
TOTAL S/HOLDERS` EQUITY |
312,217 |
307,698 |
|||
|
|
TOTAL EQUITIES |
762,118 |
761,534 |
|||
|
CONSOLIDATED CASH FLOWS |
|
|
||||
|
|
|
Terms ending: |
31/03/2012 |
31/03/2011 |
||
|
|
Cash Flows
from Operating Activities |
|
53,668 |
77,132 |
||
|
|
Cash
Flows from Investment Activities |
-35,164 |
-27,745 |
|||
|
|
Cash
Flows from Financing Activities |
-14,122 |
-42,062 |
|||
|
|
Cash,
Bank Deposits at the Term End |
|
33,283 |
28,454 |
||
|
ANALYTICAL RATIOS Terms ending: |
31/03/2012 |
31/03/2011 |
||||
|
|
|
Net
Worth (S/Holders' Equity) |
312,217 |
307,698 |
||
|
|
|
Current
Ratio (%) |
130.16 |
137.64 |
||
|
|
|
Net
Worth Ratio (%) |
40.97 |
40.41 |
||
|
|
|
Recurring
Profit Ratio (%) |
4.01 |
6.17 |
||
|
|
|
Net
Profit Ratio (%) |
1.40 |
3.09 |
||
|
|
|
Return
On Equity (%) |
3.84 |
8.18 |
||
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.86 |
|
UK Pound |
1 |
Rs.87.93 |
|
Euro |
1 |
Rs.70.88 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.